In conclusion, our analysis in acute leukemia revealed mutations in the histone-modifying enzymes recently identified to be altered in other cancers, particularly UTX in ALL and MLL2 in AML, although not at a high incidence. Important to note is that UTX and MLL2 are part of the same protein complex and both MLL2 and UTX mutations may lead to similar phenotypic consequences in cancer cells. Also, MLL2 was not fully sequenced in our analysis, leaving open the possibility of additional mutations in AML. Nevertheless, our findings warrant further analyses within larger studies and most likely more comprehensive studies based on targeted or whole genome/exome next-generation sequencing approaches. Of interest, most of the UTX mutations observed in our study were found in clinically defined high-risk patients and at least 1 of those patients (05-046) eventually relapsed. Therefore, this observation might be of particular interest with regard to potential epigenetic treatment approaches, although the exact mechanisms of transformation in UTX-mutated ALL remain to be elucidated.
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Anemia is common in cancer patients and is especially frequent in myeloma patients because of the high prevalence of renal insufficiency. Although erythropoietin (Epo) can reduce the need for blood transfusions, its use has been tempered by adverse effects on venous thromboembolism, tumor progression, and cancer survival in recent clinical trials. 1 Although some myeloma patients were included in these trials, no prospective study has evaluated the effect of Epo on survival in myeloma. Epo use was associated with significantly reduced myeloma survival in one retrospective study, 2 whereas other studies showed that Epo caused myeloma regression in mice, 3 that Epo did not impair time to progression or overall survival in patients treated with melphalan and prednisone with or without bortezomib, 4 or that Epo improved survival. 5 Whether tumor epithelial and/or endothelial cells express functional Epo receptor (EpoR) is the subject of controversy. 6 The ability to unequivocally link tumor EpoR expression with Epo treatment and clinical outcomes would provide a means for directly testing the clinical significance of tumor EpoR expression. Although EpoR mRNA levels can be reliably measured in formalinfixed, paraffin-embedded tumor tissue, 7 the detection of EpoR protein in these specimens using immunohistochemistry has been confounded by the low level of EpoR protein and by inadequate antibody specificity. 8 Using a sensitive and specific monoclonal antibody (A82), and semi-quantitative western blotting with whole-cell lysates, scientists at Amgen recently demonstrated absence or low expression of EpoR protein (o100 EpoR dimers per cell) in 54 human tumor cell lines, whereas 7 other nonerythroid cell lines expressed between 400 and 3200 EpoR dimers per cell. 9 However, this study did not examine EpoR levels in myeloma cell lines or primary tumor cells.
Unlike most solid tumors, malignant cells from the bone marrow of patients with multiple myeloma can be examined as single cells with minimal processing. This affords the opportunity to analyze EpoR surface protein levels by flow cytometry. A previous study failed to detect surface EpoR in primary Accepted article preview online 1 March 2012; advance online publication, 16 March 2012 myeloma samples using digoxigenin-labeled Epo binding detected by flow cytometry, however, this study was limited to four samples. 10 Moreover, the sensitivity of this assay was limited to 300 receptors per cell, whereas studies by Um et al. 11 suggest that, at least in certain cell lines, surface EpoR expression below this level may be functionally relevant.
We recently appended staining with the murine monoclonal FAB307P anti-EpoR antibody (R þ D Systems, Minneapolis, MN, USA) to the clinical flow cytometry of 31 bone marrow aspirates from patients with multiple myeloma. 12 Although staining with FAB307P in myeloma cells ranged from negative (essentially superimposed with the isotype control) to as high as 86% positive (mean 40% positive), the corresponding lymphocytes from these patients were uniformly negative. Overall, staining with FAB307P above isotype was observed in 450% of cases. Therefore, in the present study, we further scrutinized whether FAB307P binding in primary myeloma samples represents surface EpoR using a number of approaches.
First, we compared EpoR mRNA and FAB307P staining levels across 10 primary myeloma samples. EpoR mRNA levels were determined by quantitative real-time PCR and normalized to the reference genes HMBS, TFRC, and UBC as described. 7 However, there was no correlation between FAB307P staining and EpoR mRNA levels in the primary myeloma samples (r ¼ À0.21, n ¼ 10, P ¼ 0.3). Although discrepancies between mRNA and protein may reflect post-translational regulation, this finding raised concern as to the specificity of the FAB307P antibody in clinical specimens.
Next, we compared results using FAB307P to a sensitive and specific monoclonal antibody directed against EpoR that was recently developed by scientists at Amgen (A82). 9 First, we compared the specificity of FAB307P and A82 in the erythroid cell line, OCIM1, using shRNAs to generate sub-clones that express a 1% bovine serum albumin, 0.02% sodium azide, 250 mg/ml human immunoglobulin G (IgG), cells were incubated for 30 min on ice with 1 mg/ml FAB307P, a phycoerythrin (PE) conjugate, or 0.5 mg/ml A82. Cells stained with A82 were subsequently incubated for 30 min on ice with anti-rabbit IgG-PE (1 to 10 dilution, 111-116-144, Jackson Immunoresearch, West Grove, PA, USA). After washing, cells were analyzed by flow cytometry. COLO677 cells were used as a negative control, and UT7EPO and OCIM1 cells were used as positive controls. OCIM1 sublines expressing an shRNA directed against EpoR are designated as KD. Mean PE fluorescence values above isotype control staining are plotted for each cell line. Dead cells were excluded from analysis. Error bars represent the average deviation of duplicate determinations. (b) Staining with FAB307P or A82 plus a secondary PE antibody (red histograms), or the corresponding isotype controls (blue histograms) is shown in plasma cells from the bone marrow of patients with multiple myeloma (patients [1] [2] [3] [4] [5] [6] [7] [8] or normal donors (N1-N3). Staining events are shown in gated plasma cells, which were identified on the basis of CD45, CD38, CD138, CD19, and CD56 expression. 15 Samples from patients 1 --4 were enriched for CD138 þ cells by magnetic-activated cell sorting before staining. Dead cells were excluded from analysis. range of EpoR levels (Mission shRNA system, Sigma Aldrich, St Louis, MO, USA). COLO677 cells 9 and Epo-dependent UT7EPO cells provided negative and positive controls, respectively. This experiment revealed that both FAB307P and A82 antibodies were sensitive and specific for detecting surface EpoR protein levels in this panel of cell lines (Figure 1a) .
We then proceeded to compare staining with FAB307P and A82 in primary myeloma samples. In striking contrast to the results obtained with FAB307P, staining with A82 in primary myeloma cells and normal plasma cells was uniformly negative (Figure 1b) . This result was unexpected based on the extremely consistent manner in which these antibodies behaved across the above panel of control cell lines. One possibility to explain this result is that the FAB307P antibody is recognizing an EpoR epitope on the surface of primary myeloma cells that cannot be bound by A82. Alternatively, surface staining by FAB307P in myeloma cells may not be the result of EpoR expression.
Finally, to further assess whether FAB307P staining represents surface EpoR, we pre-treated myeloma cells with Epo before staining with FAB307P, based on the principle that internalization and degradation of EpoR is a hallmark of Epo binding. 11, 13 However, unlike in positive control OCIM1 and UT7EPO cells (Figure 2a) , the prior addition of Epo failed to diminish the intensity of FAB307P binding in primary myeloma cells (Figure 2b ). This result is consistent with the notion that FAB307P is detecting a non-EpoR protein on the surface of myeloma cells. However, we cannot exclude the possibility that FAB307P staining represents a novel EpoR form that cannot be bound by A82 and does not appear to bind/internalize Epo. Importantly, our study cannot address whether Epo may stimulate tumor epithelial cells, endothelial cells, stromal cells, or other cell types, or support primary myeloma growth, tumor progression, or evasion from chemotherapy in vivo. Our study suggests that future preclinical and clinical studies on the safety of Epo in myeloma should include the evaluation of indirect mechanisms by which Epo may stimulate tumor progression. Such studies should evaluate the effects of Epo on tumor angiogenesis, or on the bone marrow microenvironment. Regarding the latter, for example, does Epo stimulate erythroid cells or stromal cells to elicit growth factors that support myeloma growth or protection from chemotherapy?
Finally, Epo therapy is a well-recognized risk factor for venous thromboembolism, and patients with multiple myeloma are at an increased risk of this complication, especially when treated with thalidomide or lenalidomide in combination with dexamethasone or chemotherapy. 14 poorly understood. Future work is needed to understand how Epo treatment influences venous thromboembolism in myeloma and to identify patients at higher risk for this complication.
